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Abstract
Background: Autosomal-dominant polycystic kidney disease (ADPKD) is an inherited renal cystic disease
that leads to end-stage renal disease. Patients who present with symptoms at an early age are more likely to live
to develop end stage renal disease. Patients with ADPKD and renal failure are most commonly treated with
hemodialysis. Tolvaptan is expected to be effective in the treatment of ADPKD because of its success in
animal models. If clinical trials can prove slowing of the disease progression, hemodialysis and kidney
transplant for those patients may not be necessary. What is the effectiveness of tolvaptan as a treatment option
for ADPKD to inhibit renal cyst progression?
Method: An exhaustive literature search was done using the following search engines, MEDLINE, CINAHL,
EMBR, Web of Science, and the initial search used the following combined search terms as treatment, clinical
trial, and polycystic kidney disease. The bibliographies of the articles were further searched for relevant
sources. Articles with primary data evaluating ADPKD were included. Relevant articles were assessed for
quality using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE). A
search on the National Institute of Health (NIH) clinical trials site was done.
Results: Two studies met inclusion criteria and were included in this systematic review. The result of the 3
year study found tolvaptan to be significant in slowing down the total kidney volume (TKV), which is related
to the cyst progression in kidneys. Cyst growth progressed more slowly in the tolvaptan treated patients than
in the historical controls. The secondary objective of eGFR was also measured, but was not found to be
significant in maintaining the filtration rate, even though the trend is more noticeable than in the control
group. The other study was a 1-week administration of tovaptan where the result was analyzed post hoc. The
post hoc blinded analysis of renal MRI showed a significant 3.1% reduction in the TKV from baseline after 1
week of tolvaptan with P-value
Conclusion: Tolvaptan showed a positive result on inhibition of renal cysts growth in patients with ADPKD,
but it does not have a significant effect on the other outcomes, such as slowing progression of GFR, which
measures kidney’s failure and its progression to ESRD. Further studies such as TEMPO (an NIH phase 2
registered trial), may show more evidence of slowing down the disease progression and tolvaptan drug
alteration may be necessary to reduce AEs and be more of an appropriate drug to treat ADPKD.
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Abstract   
Background: Autosomal-dominant polycystic kidney disease (ADPKD) is an inherited renal cystic disease 
that leads to end-stage renal disease. Patients who present with symptoms at an early age are more likely to 
live to develop end stage renal disease. Patients with ADPKD and renal failure are most commonly treated 
with hemodialysis. Tolvaptan is expected to be effective in the treatment of ADPKD because of its success 
in animal models. If clinical trials can prove slowing of the disease progression, hemodialysis and kidney 
transplant for those patients may not be necessary. What is the effectiveness of tolvaptan as a treatment 
option for ADPKD to inhibit renal cyst progression? 
 
Method: An exhaustive literature search was done using the following search engines, MEDLINE, 
CINAHL, EMBR, Web of Science, and the initial search used the following combined search terms as 
treatment, clinical trial, and polycystic kidney disease. The bibliographies of the articles were further 
searched for relevant sources.  Articles with primary data evaluating ADPKD were included.  Relevant 
articles were assessed for quality using the Grading of Recommendations, Assessment, Development and 
Evaluation (GRADE). A search on the National Institute of Health (NIH) clinical trials site was done. 
 
Results: Two studies met inclusion criteria and were included in this systematic review. The result of the 3 
year study found tolvaptan to be significant in slowing down the total kidney volume (TKV), which is 
related to the cyst progression in kidneys. Cyst growth progressed more slowly in the tolvaptan treated 
patients than in the historical controls. The secondary objective of eGFR was also measured, but was not 
found to be significant in maintaining the filtration rate, even though the trend is more noticeable than in 
the control group. The other study was a 1-week administration of tovaptan where the result was analyzed 
post hoc. The post hoc blinded analysis of renal MRI showed a significant 3.1% reduction in the TKV from 
baseline after 1 week of tolvaptan with P-value <0.001.  
 
Conclusion: Tolvaptan showed a positive result on inhibition of renal cysts growth in patients with 
ADPKD, but it does not have a significant effect on the other outcomes, such as slowing progression of 
GFR, which measures kidney’s failure and its progression to ESRD. Further studies such as TEMPO (an 
NIH phase 2 registered trial), may show more evidence of slowing down the disease progression and 
tolvaptan drug alteration may be necessary to reduce AEs and be more of an appropriate drug to treat 
ADPKD. 
 
Keywords: Tolvaptan, treatment, clinical trial, polycystic kidney disease. 
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Tolvaptan: a Possible Treatment for Autosomal Dominant Polycystic 
Kidney Disease. 
 
BACKGROUND 
Autosomal-dominant polycystic kidney disease (ADPKD) is an inherited renal 
cystic disease that leads to end-stage renal disease. This disease occurs worldwide and in 
all races with a prevalence estimated to be between 1:400 and 1:1000 and affects males 
more than females at ratios of 1.2-1.3:1 for the early incidence rates of ADPKD which 
will progress to end-stage renal disease (ESRD) in Japan, Europe and the United States.24 
According to National Kidney Foundation (NKF) guidelines, ESRD is indicated when 
glomerular filtration rate (GFR) falls below a value of 15 ml/min per 1.73m2 with the 
need for permanent renal replacement therapy (RRT). A patient with a value between 15-
29 ml/min will need to prepare to receive RRT as treatments.28 ADPKD is genetically 
heterogeneous with 2 genes identified: PKD1 and PKD2. Autosomal-recessive polycystic 
kidney disease (ARPKD) is less common than ADPKD, but together with 
nephrophthaisis is the leading cause of ESRD in childhood.21 Virtually all individuals 
who inherit PKD1 or PKD2 eventually develop renal cysts that are visible by 
ultrasonographic imaging studies.14 The age at which affected individuals have clinical 
manifestations such as renal failure or hypertension is variable. Patients with PKD1 
present with symptoms at a younger age than those with PKD2. In one study the median 
age of patients who presented with renal failure was 54 and 74 years for those with PKD1 
and PKD2, respectively.12 However, early onset disease has been described with both 
mutations.3,22 Patients who present with symptoms at an early age are more likely to live 
to develop end stage renal disease.6,16 In one study, patients diagnosed before the age of 
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30 had a mean renal survival of 10 years less than those diagnosed after the age of 
thirty.16 Currently there is no effective therapy for these diseases. Patients with ADPKD 
and renal failure are most commonly treated with hemodialysis. Such patients have 
equivalent or perhaps better overall outcomes with any renal replacement therapy 
compared to non-ADPKD patients.19 Although beneficial, each hemodialysis session is 
not cheap to the patients and impacts their qualities of life greatly. The mean total cost of 
each maintenance hemodialysis session was estimated to be $297 USD with mean total 
annual cost of dialysis per patient estimated to be $46,332 USD.1 The earlier ADPKD 
progresses to ESRD, the higher the cost to an individual. Time taken away from the 
patients with hemodialysis impacts their livelihood, and the added cost of continued 
hemodialysis impacts our healthcare system. Advances in the understanding of 
cytogenesis and availability of genetically related animal models provide unique 
opportunities to develop effective treatments.21 If the progression of ADPKD can be 
slowed to reach ESRD at a much later stage in life, not only will the patient benefit, but 
the impact on the cost of our healthcare support systems will be dramatic.  
 So what causes cysts to form in ADPKD? Within our kidneys polycysteins and 
fibrocystein/polyductin are multifunctional proteins with numerous interacting partners 
that are essential in maintaining the differentiated phenotype of the tubular epithelium.23 
Reduction in one of these proteins below a critical level induces changes in protein 
trafficking and targeting, cell-matrix and cell-to-cell interactions, proliferation and 
apoptosis, planar polarity, and fluid secretion that result in the nitration and growth of 
cysts.25 In theory, increased collection duct permeability to water and concentrated 
urinary osmolality above that of plasma, causes cyst growth which is “clamped” by 
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vasopressin.9  The treatment of patients with ADPKD includes non-specific measures that 
are applicable to all ESRD patients, such as strict blood pressure control, dietary protein 
restriction, a low salt diet, and statins, which may prevent progression of disease and 
reduce cardiovascular mortality.  
Currently there are some new treatments that are being explored. Treatment such 
as Small-molecule cystic fibrosis transmembrane conductance regulator (CFTR) 
inhibitors and V2-receptor antagonists show promising effects of slow cyst growth in 
laboratory animals. There are no published clinical trials performed for CFTR inhibitors 
at this time but there are a few trials that were recently completed for V2-receptor 
antagonists.  
Tolvaptan is an orally effective nonpeptide arginine vasopressin (AVP) V2-
receptor antagonist. It inhibits not only the binding of AVP, but also the AVP-induced 
production of cyclic adenosine monophosphate (cAMP) . In addition, tolvaptan has no 
intrinsic V2 receptor agonistic effect.18 There is clear evidence that cAMP plays a major 
role in cystogenesis. The AVP V2-receptor pathway is a major pathway for cAMP 
accumulation in the renal collecting ducts. The V2-receptor antagonists could be useful in 
the treatment of PKD.2  The FDA approved its current use for treatment of clinically 
significant hypervolemic or euvolemic hyponatremia. Tolvaptan showed marked 
aquaresis in healthy and diseased animals. In rat models with acute and chronic 
hyponatremia, tolvaptan improved organ water retention and increased survivability. 
Miyazaki et al18 showed tolvaptan reduced cardiac preload without unfavorable effects on 
renal functions, systemic hemodynamics, and circulating neurohormones in dogs with 
heart failure (HF). Furthermore, in animal models of human polycystic kidney disease, 
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use of tolvaptan showed a decrease in kidney weight as well as in cyst and fibrosis 
volume.18  
The purpose of this study is to explore the effectiveness of a possible treatment 
that is in current clinical trials. Tolvaptan is indicated as a useful therapy in 
hyponatremia, HF and other diseases that are accompanied by volume overload. 
Furthermore, tolvaptan is also expected to be effective in the treatment of ADPKD.  If 
clinical trials can prove slowing of the disease progression, the need for hemodialysis and 
kidney transplant for those patients may not be necessary. Therefore this review aims to 
determine the effectiveness of tolvaptan as a treatment option for inhibiting renal cyst 
growth in people with ADPKD. 
METHODS 
An exhaustive literature search was done using the following search engines, 
MEDLINE, CINAHL, EMBR, Web of Science, and the initial search used the following 
combined search terms as treatment, clinical trial, and polycystic kidney disease. The 
bibliographies of the articles were further searched for relevant sources.  Articles with 
primary data evaluating ADPKD were included.  A search on the National Institute of 
Health (NIH) clinical trials site was conducted. Relevant articles were assessed for 
quality using the Grading of Recommendations, Assessment, Development and 
Evaluation (GRADE).27 
RESULTS 
  The results returned from MEDLINE revealed 55 relevant articles, CINAHL 3, 
and EBMR 2. Only 2 articles from this search met inclusion criteria with clinical trials of 
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tolvaptan for the purpose of treatment in ADPKD.  These articles include one randomized 
controlled trial13 and one blinded post hoc analysis.15 Both studies were funded by Otsuka 
Pharmaceutical Development & Commercialization Inc. In addition, the search of the 
NIH clinical trial database revealed one currently registered completed trial of a Phase 2, 
multi-center, open-label study to determine long-term safety, tolerability, and efficacy of  
split-dose oral regimens of tolvaptan tablets in a range of 30 to 120 mg/d in patients with 
autosomal dominant polycystic kidney disease which will not be included as part of the 
review since it is not fully analysed.26  
The 3-Year Study 
 This study13 is a Phase 2 clinical trial where consenting ADPKD patients were 
enrolled in two multicenter open-label tolvaptan-treatment studies in North America and 
Japan. For the North American study, eligibility requirements were men or women age 
>18 years fulfilling Ravine’s diagnostic criteria,20 prior participation in a phase 1 
tolvaptan ADPKD trial, and willingness to adhere to contraceptive precaution. Ravine’s 
diagnostic criteria (RDC) is explained by the authors as (explaination from study). 
Exclusion criteria included inability to comply with study procedures, estimated 
glomerular filtration rate (eGFR) <30ml/min per 1.73 m2, anticipation of renal 
replacement therapy within 1 year, and active treatment that would affect endpoint 
measurements. The Japanese study was similar except for participants were enrolled at 
age 20 years without upper limit and also had further exclusion that included subjects 
with serum creatinine ≥ 2.5mg/dl, uncontrolled hypertension, systolic BP <90 mmHg, 
serious cardiac or hepatic disease, or a history of significant bleeding or bleeding 
tendency. A total of 63 subjects started the regimen of tolvapan at various split-doses 
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depending on the tolerance of each patient and 12 subjects were lost prior to the end of  
the study which lasted 36 months 6 of whom withdrew due to adverse events (AE). The 
remaining 6 were unaccounted for.13 
 The primary objective of this trial was to confirm the long-term safety and 
tolerability of tolvaptan. Subject safety was assessed by regular monitoring of adverse 
events, directed physical examination, vital signs, laboratory, and electrocardiogram 
measurement. The secondary objective of this trial was to acquire pilot efficacy data by 
assessing changes in urine osmolality, total kidney volume (TKV), estimated glomerular 
filtrate, and hypertension status. Control data were gathered from participants in the 
Consortium of Radiologic Imaging Studies of Polycystic Disease (CRISP) and 
Modification of Diet in Renal Disease (MDRD) studies.17,29 The first control subject was 
matched to the first tolvaptan-treated subject and then the second control was matched to 
the second tolvaptan-treated subject, and so on until all had one match similar to the 
treated subject. The process then proceeded in again, selecting a second similar control 
subject for the tolvaptan-treated subject who was last matched until all had two control 
matches for every study subject. Therefore, a total of 102 control match subjects were 
included in this study for comparison.13  
 The result of this study13 found tolvaptan to be significant in slowing down the 
total kidney volume (TKV), which is related to the cyst progression in kidneys. Cyst 
growth progressed more slowly in the tolvaptan treated patients than in the historical 
controls. Eighty-one percent of subjects completed 3 years of treatment. Although all of 
the participants experienced AEs and six participants withdrew from the study because of 
AEs, most were mild to moderate in severity. The author stated that tolvaptan had a 
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strong effect on TKV growth, consistent with a potent effect on cyst growth. The growth 
of cysts appears to resume beyond 6 months but at a much slower rate than in the control 
group. The secondary objective of eGFR was also measured, but was not found to be 
significant in maintaining the filtration rate, even though the trend is more noticeable than 
in the control group. The mean change in eGFR over 3 years of treatment with tolvaptan 
was marginally less than in the control group even though the tolvaptan group had larger 
kidney size at baseline. The authors recognized this study has limitations. Twelve of 51 
of the tolvaptan-treated patients were Japanese whereas both of the matched-control 
patient cohorts were predominantly Caucasian with only approximately 1% Asian. 
Another limitation is that controls were not studied concurrently.13 
 Lastly, only 8 out of 51 study subjects were not receiving antihypertensive 
therapy at the beginning of the study and by the end, 3 became hypertensive during the 3 
years of treatment.13  
The 1-Week Study 
 In this particular 1 week duration study,15 the result of TKV was a blinded post 
hoc analysis. Post hoc hypotheses based on subgroup analysis often arise from 
exploration of a data set in which many such hypotheses are considered.11 The original 
purpose of the study was to clarify the potential renal mechanisms to see whether the 
antagonist effects were dependent on underlying renal function in 20 patients with 
ADPKD before and after 1 week of daily split-dose treatment. Participating ADPKD 
patients were previously diagnosed base on Ravine’s criteria, 18-60 years of age and 
selected to represent a wide range of disease severity with estimated creatinine clearance 
(eCCr) by the Cockcroft-Gault equation ≥ 30ml/min. A total 20 participants (10 
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caucasian males and 10 caucasian females) were enrolled in the study. Exclusion criteria 
included concurrent diseases that could interfere with the conduct of the study or the 
interpretation of the results. This was a single center, sequential, multiple-dose study of 
the effect of split-dose tolvaptan tablets on ADPKD patients. Subjects were given enough 
tablets for 7 days with 45 mg on awakening and 15mg 8 hrs later on study days 1-6. On 
day 7, subjects administered tolvaptan 45mg on awaking at home and administered 
additional 15mg 8hrs later at the study facility. On day 8, subjects were given 45mg 
doses at the study facility then followed by measurement of renal clearance, renal blood 
flow by MRI, and chemistry and hematology parameters.15 
 The goal of this study15 was to check various effects of tolvaptan on laboratory 
parameters. Changes in TKV were not an initial focus for this study since it had been 
believed that it would take months to detect the effects due to inhibition of cell 
proliferation or fluid secretion. The post hoc blinded analysis of renal MRI showed a 
significant 3.1% reduction in the TKV from baseline after 1 week of tolvaptan with P-
value <0.001. In order to determine whether the reduction in kidney volume was due to 
changes in the cyst volume, individual cyst size was measured in 9 patients. To protect 
against bias, the MRI scan was blinded to the examiner by de-identified patients and the 
removal of the date of examination. In 8 of the 9 patients, the mean cyst volume was 
lower following administration of tolvaptan and in 3 of them the change was statistically 
significant. The researches suggest that early decrease in TKV, is likely attributable to 
changes in cyst fluid secretion.15 
 The result also showed the administration of tolvaptan increases urine flow, and 
free water clearance, and induced an 8.6% reduction in GFR. However, there was no 
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correlation between percent changes in GFR and GFR value at baseline with a P-value = 
0.398. It is unlikely that relative concentration of plasma volume accounts for the 8.6% 
reduction in GFR, since no significant change in blood hemoglobin or serum protein or 
albumin concentration was detected.15  
DISCUSSION 
Tolvaptan is currently approved in the US and EU for the treatment of 
hyponatremia in euvolemic and hypervolemic states and syndrome of inappropriate 
antidiuretic hormone hypersecretion (SIADH).15 The drug was designed for patients with 
disorders such as HF, liver cirrhosis, impaired renal function, and SIADH due to excess 
water retention.18 It has recently realized that it might be effective in the treatment of 
PKD due to its mechanism of actions. Several recent studies show tolvaptan to be 
effective in animal models in demonstrating that vasopressin stimulates renal cytogenesis 
by increasing intracellular cAMP, which promotes transepithelial fluid secretion and 
stimulates cyst-derived cell proliferation in vitro.18 Therefore, tolvaptan is expected to 
become a useful drug in the treatment of PKD. The two clinical trials, the 3-year and 1-
week studies do suggest such an effective mechanism in significantly slowing down renal 
cysts progression in ADPKD patients. However, there are many limitations that still 
result in this drug not being being fully utilized in a clinical setting. These limitations 
include but are not limited to clinical trial sample size, the number of adverse events, and 
the length treatment and follow up. 
The sample size in the 3-year study13 began at 63 study subjects, of whom 12 
(19%) withdrew from the study. Although the size was considered decent, greater 
numbers of study subjects will be necessary in order to calculate more precise statistical 
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values. The 3-year study13 showed statistical significance of in how tolvaptan slowed 
progression in TKV, other secondary outcomes may become clearer with a larger sample 
size. The authors revealed that 6 of those lost to follow up withdrew due to AEs, but do 
not account for the other 6. The reasons behind the losses may be important in ensuring 
full transparency in a study funded primarily by Otsuka Pharmaceutical Development & 
Commercialization Inc. who developed the drug.  Another limitation of this study was the 
lack of a concurrent control group during the 3 year period. The control data were pulled 
from CRISP and MDRD to match the study subjects. The authors did not clarify how the 
controls were matched to the study subjects, although later comments in the results 
indicate that it was not a racial match as Caucasian controls were matched with Japanese 
study subjects. Neither was it a consideration of kidney size as it was later found that the 
matched controls started off with unequal kidneys. Another problem with matching 
seems to be that all of the treatment group were treated for 3 years and the controls 
appear to have been selected from data in historical files only at the end of the study. 
Although the data is useful for comparison in this study, the concurrent control group 
would have eliminated doubts of other situational or environmental factors affecting the 
outcome of the results, and how the controls were match to the study subjects. The 
authors also report an 81% completion rate which sounds like a positive result, however, 
this is misleading as this also means that there was a 19%  loss to follow up, which is 
rather a high number. In the other study,15 which only lasted 1 week, the sample size of 
20 participants is not only small but also lacks diversity. All patients in that study were 
Caucasian and accordingly the result are only generalizable to such a population group. 
No control group was utilized concurrently with this study. 
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In the 3-year study13 of tolvaptan all the AEs that occurred associated with the 
drug were well documented. Higashihara et al13 identified that the most prominent AEs 
were thirst, abnormally frequent urination, renal pain and upper urinary tract infection 
with higher occurrences at higher split dosage (90/30 mg/d) of tolvaptan. AEs were 
accounted for in all subjects participated in the study, and included renal impairment, 
acute renal failure, benign pituitary tumor, transient ischemic attack, eye swelling, and 
subarachnoid hemorrhage with fatal outcome.13 Since one may have had a fatal outcome, 
very little information was given as to this specifics although as it was included in the list 
of AEs, this seems to be an acknowledgement that it was drug related. In the 1-week 
study15 of tolvaptan, the common AEs were similar to those of the 3-year study13, which 
included polyuria, polydipsia, nocturia and dry mouth. It is reasonable to assume that the 
less serious AEs referred to in the 1-week study15 were because the patient were only 
given tolvaptan for 8 days. If the patient had taken long term tolvaptan, the AEs may 
have mimicked those of the longer study up to and including fatal outcomes. These 
studies demonstrated that the AEs from tolvaptan were moderately tolerated by most 
patients. The loss to follow up due to AEs in the 3-year study13 demonstrated serious 
limitations of in clinical administration of this drug. A further study in greater sample 
size is necessary to better define the size of population it would affect. 
Tolvaptan showed significant difference in slowing progression of renal cysts 
during the 3 year span of the study. However, other secondary outcomes may require 
longer period of time to achieve a significant result. For example, the GFR measurement 
shows tolvaptan was able to maintain GFR during the study period, however, the mean 
changes did not result in a P-value that render the data significant. The mean change 
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measurements of patients on tolvaptan show smaller changes in GFR according to Table 
4 in the 3-year study by Higashihara et al.13 The significance of the GFR changes may 
not be apparent without a much longer study period. A longer study period involving 
tolvaptan is necessary to measure the secondary outcomes of disease progression to 
ESRD. 
Tolvaptan is continually studied as a treatment option for ADPKD. A design of 
Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic 
Kidney Disease and Its Outcome (TEMPO)26 study was recently completed in February 
2012 but is not yet available. It will be interesting to see the results of this new study. 
This TEMPO study seeks to determine whether tolvaptan inhibits TKV growth in patients 
with ADPKD whether such changes meaningfully affect the clinical course of the 
disease. The study design is a retrospective, 3 year, multicenter, double-blinded, placebo-
controlled trial of tolvaptan with approximately 1,445 patients with ADPKD enrolled 
between March 2007 and January 2009. This randomized trial is the largest clinical study 
of proposed ADPKD intervention to date. The outcome of this study may better justify 
tolvaptan’s effect on renal cysts growth and GFR. 
CONCLUSION 
 Although tolvaptan has a positive result on inhibition of renal cysts growth in 
patients with ADPKD, it does not have a significant effect on the other outcomes, such as 
slow progression of GFR, which measures kidney’s failure and its progression to ESRD. 
Tolvaptan does not have sufficient evidence in clinical setting for the use of treatment for 
ADPKD at this time, perhaps further studies such as TEMPO, will show more evidence 
of slowing down the disease progression. Furthermore, tolvaptan drug alteration may be 
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necessary to reduce AEs and become a more appropriate drug to treat ADPKD. 
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TABLES 
Table 1: GRADE Quality of Assessment and Summary of Findings: What is the effectiveness of tolvaptan as a treatment option for autosomal dominant polycystic kidney disease to inhibit renal cyst 
progression? 
+ Lack of appropriate description of case and control matching 
++Small and isolated sample 
*= unit of ml/min/1.73 m2 
**= participant became hypertensive 
 
Quality Assessment Summary of Findings 
Importance Study Details Downgrade Criteria Participant Treatment effect % changes 
Quality 
Study Design Limitations Indirectness Imprecision Inconsistency Publication bias likely Tolvaptan Control Tolvaptan Control Tolvaptan Control 
Total Kidney Volume (TKV) 
3-year Case-Control Serious limitation+ 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
Bias likely- 51 102 +98ml +300ml 5.3 19 Very Low Important 
1-week 
Post hoc 
analysis 
Serious 
limitations++ 
No serious 
indirectness 
Not serious 
imprecision overall 
No serious 
inconsistencies 
No bias likely 20 - -3.1ml - -3.1 - Very Low Important 
Estimated Glomerular Filtration Rate 
3-year Case-Control Serious limitation+ 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
Bias likely 51 101 -5.7  * -6.5 * -5.7 -6.8 Very Low Important 
1-week 
Post hoc 
analysis 
Serious 
limitations++ 
No serious 
indirectness 
Not serious 
imprecision overall 
No serious 
inconsistencies 
No bias likely 20 - -6.9  * - -8.6 - Very Low Important 
Hypertension status 
3-year Case-Control Serious limitation+ 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
Bias likely 8 - 3** - 38 - Very Low Important 
1-week 
Post hoc 
analysis 
Serious 
limitations++ 
No serious 
indirectness 
Not serious 
imprecision overall 
No serious 
inconsistencies 
No bias likely Antihypertensive regiment for study participants included Very Low Important 
